US5422260A
(en)
*
|
1986-05-29 |
1995-06-06 |
Genetics Institute, Inc. -Legal Affairs |
Human factor VIII:c muteins
|
IL86693A
(en)
|
1987-06-12 |
1994-06-24 |
Stichting Centraal Lab |
Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
SE465222C5
(sv)
*
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
DE69101634T4
(de)
*
|
1990-01-26 |
1994-12-01 |
Immuno Ag |
Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
|
FR2657884B1
(fr)
|
1990-02-05 |
1994-09-02 |
Tm Innovation |
Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
US5661008A
(en)
*
|
1991-03-15 |
1997-08-26 |
Kabi Pharmacia Ab |
Recombinant human factor VIII derivatives
|
DE69229390T2
(de)
*
|
1991-08-26 |
1999-11-11 |
Immuno Ag, Wien |
Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
|
DK53792D0
(da)
*
|
1992-04-24 |
1992-04-24 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af proteiner
|
CA2149212A1
(en)
*
|
1992-11-17 |
1994-05-26 |
Mirella Ezban Rasmussen |
Improved recombinant production of proteins having factor viii:c activity
|
SE504074C2
(sv)
*
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
DE4437544A1
(de)
*
|
1994-10-20 |
1996-04-25 |
Behringwerke Ag |
Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
EP1038959A1
(en)
|
1999-03-17 |
2000-09-27 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
|
EP1233064A1
(en)
|
2001-02-09 |
2002-08-21 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Modified factor VIII cDNA and its use for the production of factor VIII
|
EP1284290A1
(en)
*
|
2001-08-08 |
2003-02-19 |
Aventis Behring GmbH |
Increase of the expression levels of factor VIII by insertion of spliceable nucleotide sequences into factor VIII cDNA
|
WO2003057709A2
(en)
*
|
2001-10-19 |
2003-07-17 |
Sirna Therapeutics, Inc |
Method and reagent for the detection of proteins and peptides
|
EP1424344A1
(en)
*
|
2002-11-29 |
2004-06-02 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Modified cDNA factor VIII and its derivates
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
CA3072423A1
(en)
|
2003-09-30 |
2005-04-14 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
WO2006033854A2
(en)
*
|
2004-09-07 |
2006-03-30 |
Archemix Corp. |
Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
|
US20070066551A1
(en)
*
|
2004-09-07 |
2007-03-22 |
Keefe Anthony D |
Aptamer medicinal chemistry
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
EP1707634A1
(en)
|
2005-03-29 |
2006-10-04 |
Octapharma AG |
Method for isolation of recombinantly produced proteins
|
ES2580044T3
(es)
|
2005-04-07 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
CA2679107C
(en)
|
2007-02-23 |
2018-01-16 |
Sk Chemicals Co., Ltd. |
Process for producing and purifying factor viii and its derivatives
|
US20090203766A1
(en)
*
|
2007-06-01 |
2009-08-13 |
Archemix Corp. |
vWF aptamer formulations and methods for use
|
EP3581579A1
(en)
|
2009-02-03 |
2019-12-18 |
Amunix Pharmaceuticals, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
JP5813641B2
(ja)
|
2009-08-24 |
2015-11-17 |
アムニクス オペレーティング インコーポレイテッド |
凝固第ix因子組成物ならびにそれを製造および使用する方法
|
SG10201907152YA
(en)
|
2009-12-06 |
2019-09-27 |
Bioverativ Therapeutics Inc |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
WO2011095604A1
(en)
|
2010-02-04 |
2011-08-11 |
Octapharma Biopharmaceuticals Gmbh |
Half-life prolongation of proteins
|
JP5922095B2
(ja)
|
2010-03-29 |
2016-05-24 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
薬理学的に誘導される導入遺伝子アブレーション系
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
NZ605400A
(en)
|
2010-07-09 |
2015-05-29 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
US9884071B2
(en)
|
2011-02-17 |
2018-02-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
|
PT2717898T
(pt)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Compostos pró-coagulantes e processos para a sua utilização
|
BR112014000466A2
(pt)
|
2011-07-08 |
2017-02-21 |
Biogen Idec Hemophilia Inc |
polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
|
EA028914B1
(ru)
|
2011-07-25 |
2018-01-31 |
Байоджен Хемофилия Инк. |
Исследования для мониторинга нарушений свертываемости крови
|
CA2850579A1
(en)
|
2011-10-18 |
2013-04-25 |
Carsten Horn |
Method for improving the stability of purified factor viii after reconstitution
|
RS57936B1
(sr)
|
2012-01-12 |
2019-01-31 |
Bioverativ Therapeutics Inc |
Smanjenje imunogenosti na faktor viii kod osoba na terapiji faktorom viii
|
PL2804623T3
(pl)
|
2012-01-12 |
2020-03-31 |
Bioverativ Therapeutics Inc. |
Chimeryczne polipeptydy czynnika viii i ich zastosowania
|
MY188897A
(en)
|
2012-02-15 |
2022-01-12 |
Bioverativ Therapeutics Inc |
Factor viii compositions and methods of making and using same
|
BR112014019901A8
(pt)
|
2012-02-15 |
2018-01-02 |
Biogen Idec Inc |
Proteínas de fator viii recombinante
|
WO2013185113A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
キメラ性凝固因子
|
EP2870250B2
(en)
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
BR112015000267B1
(pt)
|
2012-07-11 |
2023-01-24 |
Bioverativ Therapeutics Inc. |
Proteínas quiméricas, e composição farmacêutica
|
EP2877202A4
(en)
|
2012-07-25 |
2016-06-01 |
Biogen Ma Inc |
BLOOD FACTOR MONITORING TEST AND USES THEREOF
|
EP2908847B1
(en)
|
2012-10-18 |
2022-03-30 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
EP3943102A1
(en)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
LT3889173T
(lt)
|
2013-02-15 |
2023-10-10 |
Bioverativ Therapeutics Inc. |
Optimizuotas viii faktoriaus genas
|
SG10201805207QA
(en)
|
2013-03-15 |
2018-07-30 |
Bioverativ Therapeutics Inc |
Factor viii polypeptide formulations
|
EP2968498A4
(en)
|
2013-03-15 |
2016-09-07 |
Biogen Ma Inc |
PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
SG11201509313PA
(en)
|
2013-06-28 |
2016-01-28 |
Biogen Ma Inc |
Thrombin cleavable linker with xten and its uses thereof
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
EP3082848B1
(en)
|
2013-12-06 |
2023-10-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
SI4176894T1
(sl)
|
2014-01-10 |
2024-07-31 |
Bioverativ Therapeutics Inc. |
Himerni proteini faktorja VIII in njihova uporaba
|
EP3097118B1
(en)
|
2014-01-20 |
2018-07-18 |
Octapharma AG |
A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
|
EP3102589A1
(en)
|
2014-02-04 |
2016-12-14 |
Biogen MA Inc. |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
CN115074366A
(zh)
|
2015-04-16 |
2022-09-20 |
埃默里大学 |
用于肝脏中蛋白质表达的重组启动子和载体及其用途
|
TWI741992B
(zh)
|
2015-08-03 |
2021-10-11 |
美商百歐維拉提夫治療公司 |
因子ix融合蛋白以及其製備及使用方法
|
KR20230008256A
(ko)
|
2015-11-13 |
2023-01-13 |
다케다 야쿠힌 고교 가부시키가이샤 |
A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
|
JP6695426B2
(ja)
|
2015-11-13 |
2020-05-20 |
バクスアルタ インコーポレイテッド |
組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
|
EP4137570A1
(en)
|
2016-02-01 |
2023-02-22 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
US11046749B2
(en)
|
2016-06-24 |
2021-06-29 |
Mogam Institute For Biomedical Research |
Chimera protein comprising FVIII and vWF factors, and use thereof
|
MA46968A
(fr)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc |
Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
|
IL308416A
(en)
|
2016-12-02 |
2024-01-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
WO2019032898A1
(en)
|
2017-08-09 |
2019-02-14 |
Bioverativ Therapeutics Inc. |
NUCLEIC ACID MOLECULES AND USES THEREOF
|
CN111655230A
(zh)
|
2017-11-07 |
2020-09-11 |
拉尼医疗有限公司 |
使用可吞服药物递送装置递送到肠道组织中的凝血因子制剂
|
KR20200118089A
(ko)
|
2018-02-01 |
2020-10-14 |
바이오버라티브 테라퓨틱스 인크. |
인자 viii을 발현하는 렌티바이러스 벡터의 용도
|
WO2019195055A1
(en)
|
2018-04-04 |
2019-10-10 |
Sigilon Therapeutics, Inc. |
Implantable particles and related methods
|
KR20210020030A
(ko)
|
2018-05-18 |
2021-02-23 |
바이오버라티브 테라퓨틱스 인크. |
A형 혈우병의 치료 방법
|
KR20210034013A
(ko)
|
2018-07-16 |
2021-03-29 |
박스알타 인코퍼레이티드 |
발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
|
WO2020033863A1
(en)
|
2018-08-09 |
2020-02-13 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
JP2022517267A
(ja)
|
2019-01-16 |
2022-03-07 |
バクスアルタ インコーポレイテッド |
血友病aの遺伝子療法のための発現が上昇した組換えfviiiバリアントをコードするウイルスベクター
|
US20220233650A1
(en)
|
2019-06-19 |
2022-07-28 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii-fc for treating hemophilia and low bone mineral density
|
CN114981299A
(zh)
|
2019-12-12 |
2022-08-30 |
武田药品工业株式会社 |
使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
|
CA3188420A1
(en)
|
2020-08-07 |
2022-02-10 |
Joseph Bauman |
Vesicle targeting proteins and uses of same
|
WO2022264040A1
(en)
|
2021-06-14 |
2022-12-22 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
JP2024532262A
(ja)
|
2021-08-23 |
2024-09-05 |
バイオベラティブ セラピューティクス インコーポレイテッド |
最適化第viii因子遺伝子
|
AU2022355088A1
(en)
|
2021-09-30 |
2024-05-16 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|